Agios gets $1.8bn and a new focus
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Philips spends nearly $3bn to integrate Biotelemetry
The deal is a late entrant into 2020's top five mergers and acquisitions.
Recycling pays off for Mereo
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Gilead would rather forget filgotinib
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
Finding the next Prevail
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Alexion ticks Astra’s boxes
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
Ror1 delivers its second takeout in five weeks
Boehringer Ingelheim buys NBE-Therapeutics, the second Ror1-focused player to be taken out in just over a month.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
The pandemic response roars on
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
